A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies
A Phase 1/2, Open Label, Multicenter, Multi-cohort Study of S241656 as Monotherapy or in Combination With Other Antileukemic Agents in Participants With Selected Myeloid Malignancies
The objective of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of S241656 and to determine the recommended dose for expansion (RDE) of S241656 in participants with relapsed/refractory (R/R) acute myeloid leukemia (AML), myelodysplastic syndrome/acute myeloid leukemia (MDS/AML), or chronic myelomonocytic leukemia (CMML). Part 1A dose escalation will determine the RDE to be used in a future expansion stage of the trial. An optional Part 1B drug-drug interaction (DDI) substudy will evaluate the effect of posaconazole on the PK of S241656.
The study consists of a screening period of up to 21 days, a treatment period consisting of continuous 28-day cycles of treatment, an end-of-treatment visit, a safety follow-up period, and long-term disease and survival follow-up every 3 months. Participants in the optional DDI substudy may continue treatment in the main study following completion of the DDI assessment period. Participants may undergo bone marrow aspirates and/or biopsies, blood tests, electrocardiograms (ECGs), echocardiograms or multigated acquisition (MUGA) scans, physical examinations, ophthalmologic assessments, and disease response questionnaires.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 2
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Institut de Recherches Internationales Servier (I.R.I.S.)
- Número de teléfono: +33 1 55 72 60 00
- Correo electrónico: scientificinformation@servier.com
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
- Investigator-assessed life expectancy of ≥ 3 months.
- Able and willing to comply with requirements of the study protocol.
- Documented genetic characterization of the disease as per local practice.
- Clinical and laboratory thresholds:
- Cytoreduction: white blood cell (WBC) < 25 × 10⁹/L (hydroxyurea/cytarabine/leukapheresis allowed).
- Renal: creatinine clearance (CrCl) ≥ 60 mL/min (Cockcroft-Gault).
- Hepatic: aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN) (5 × if leukemic); Total bilirubin ≤ 1.5 × ULN (≤ 3 × ULN for Gilbert's syndrome).
- Part 1 Only: Relapsed/Refractory (R/R), pathologically confirmed AML, MDS/AML, or CMML.
- Part 1 Only: Must have failed ≥ 1 approved standard therapy and have no other approved standard options.
Exclusion Criteria:
- Known hypersensitivity to S241656, or Posaconazole (Part 1B).
- Pregnant or breastfeeding; positive serum pregnancy test for WOCBP.
- Diagnosis of acute promyelocytic leukemia (French-American-British [FAB] M3 classification), MPN, mixed/ambiguous lineage, histiocytic/dendritic cell neoplasms, or AML with isolated extramedullary disease (no marrow/blood involvement).
- Active Central Nervous System (CNS) disease (by cytologic or radiographic evidence).
- Failure to recover to ≤ Grade 1 from previous toxicities (except Grade 2 neuropathy/alopecia).
- Major surgery within 4 weeks.
- Any anticancer therapy within 2 weeks or 5 half-lives (28 days for biologics). Cytoreduction with hydroxyurea or cytarabine is permitted.
- Prior use of experimental KRAS/BRAF/MEK/ERK inhibitors (prior FLT3 inhibitors are permitted).
- Uncontrolled infections (human immunodeficiency virus (HIV)/hepatitis B virus (HBV)/hepatitis C virus (HCV) permitted only if viral load is undetectable/controlled and specific cluster of differentiation 4 (CD4)+ criteria are met).
- Malabsorption, Crohn's, or chronic vomiting that impacts oral drug absorption.
- History/risk of retinal vein occlusion (RVO), glaucoma, or hyper-viscosity syndromes.
- Other active malignancy requiring systemic therapy within 2 years (except non-melanoma skin cancer or localized/cured tumors).
- Stroke, myocardial infarction (MI), unstable angina, or acute coronary syndrome within 6 months.
- Congestive heart failure (CHF), clinically significant cardiac arrhythmias according to the investigator's judgement (e.g., ventricular tachycardia), complete left bundle branch block and high-grade atrioventricular (AV) block (e.g., bifascicular block, Mobitz type II- and third degree AV block).
- Fridericia-corrected QT interval (QTcF) > 470 msec or history of Torsades de pointes.
- Disseminated intravascular coagulation (DIC), significant coagulopathy according to the investigator's judgement, or uncontrolled bleeding.
- Proton Pump Inhibitors (PPIs) and potassium-competitive acid blockers ≥ 7 days prior to Cycle 1 Day 1.
- Breast cancer resistance protein (BCRP) sensitive substrate or with a narrow therapeutic index (NTI)
- All herbal preparations/supplements are prohibited.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación Secuencial
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Part 1A: Dose Escalation
|
Tablets taken by mouth.
|
|
Experimental: Part 1B: Optional Drug-Drug Interaction [DDI] Substudy
|
Tablets taken by mouth.
Tablets taken by mouth
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
(Part 1A and 1B) Dose limiting toxicity (DLTs) associated with S241656 during the first cycle of treatment
Periodo de tiempo: Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
|
(Part 1A and 1B) Number of Adverse Events (AEs)
Periodo de tiempo: Through 30 days after the last dose of treatment, up to approximately 4 years
|
Through 30 days after the last dose of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Number of Serious Adverse Events (SAEs)
Periodo de tiempo: Through 30 days after the last dose of treatment, up to approximately 4 years
|
Through 30 days after the last dose of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Severity of AEs
Periodo de tiempo: Through 30 days after the last dose of treatment, up to approximately 4 years
|
Through 30 days after the last dose of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Severity of SAEs
Periodo de tiempo: Through 30 days after the last dose of treatment, up to approximately 4 years
|
Through 30 days after the last dose of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Duration of AEs
Periodo de tiempo: Through 30 days after the last dose of treatment, up to approximately 4 years
|
Through 30 days after the last dose of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Duration of SAEs
Periodo de tiempo: Through 30 days after the last dose of treatment, up to approximately 4 years
|
Through 30 days after the last dose of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Number of changes in safety laboratory results
Periodo de tiempo: Through 30 days after the last dose of treatment, up to approximately 4 years
|
Through 30 days after the last dose of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Number of changes in physical examination
Periodo de tiempo: Through 30 days after the last dose of treatment, up to approximately 4 years
|
Through 30 days after the last dose of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Number of dose reductions due to AEs
Periodo de tiempo: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Number of dose interruptions due to AEs
Periodo de tiempo: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Number of dose delays due to AEs
Periodo de tiempo: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Number of study withdrawals due to AEs
Periodo de tiempo: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
(Part 1B only) Maximum concentration (Cmax) of S241656
Periodo de tiempo: Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
|
(Part 1B only) Cmax of metabolite S243796
Periodo de tiempo: Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
|
(Part 1B only) Time corresponding to Cmax (Tmax) of S241656
Periodo de tiempo: Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
|
(Part 1B only) Tmax of metabolite S243796
Periodo de tiempo: Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
|
(Part 1B only) Terminal half-life (t1/2) of S241656
Periodo de tiempo: Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
|
(Part 1B only) t1/2 of metabolite S243796
Periodo de tiempo: Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
|
(Part 1B only) Area under the curve (AUC) of S241656
Periodo de tiempo: Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
|
(Part 1B only) AUC of metabolite S243796
Periodo de tiempo: Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
(Part 1A only) Cmax of S241656
Periodo de tiempo: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
|
(Part 1A only) Cmax of metabolite S243796
Periodo de tiempo: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
|
(Part 1A only) Tmax of S241656
Periodo de tiempo: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
|
(Part 1A only) Tmax of metabolite S243796
Periodo de tiempo: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
|
(Part 1A only) AUC of S241656
Periodo de tiempo: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
|
(Part 1A only) AUC of metabolite S243796
Periodo de tiempo: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
|
(Part 1A only) t1/2 of S241656
Periodo de tiempo: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
|
(Part 1A only) t1/2 of metabolite S243796
Periodo de tiempo: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
|
(Part 1A and 1B) Complete remission (CR)
Periodo de tiempo: Through study completion, approximately 4 years
|
Through study completion, approximately 4 years
|
|
|
(Part 1A and 1B) Complete remission with incomplete hematologic recovery (CRi)
Periodo de tiempo: Through study completion, approximately 4 years
|
In participants with AML or MDS/AML only
|
Through study completion, approximately 4 years
|
|
(Part 1A and 1B) Morphologic leukemia free state (MLFS)
Periodo de tiempo: Through study completion, approximately 4 years
|
In participants with AML or MDS/AML only
|
Through study completion, approximately 4 years
|
|
(Part 1A and 1B) Complete remission with partial hematologic recovery (CRh)
Periodo de tiempo: Through study completion, approximately 4 years
|
In participants with AML or MDS/AML only
|
Through study completion, approximately 4 years
|
|
(Part 1A and 1B) Partial response (PR)
Periodo de tiempo: Through study completion, approximately 4 years
|
Through study completion, approximately 4 years
|
|
|
(Part 1A and 1B) Objective response (OR)
Periodo de tiempo: Through study completion, approximately 4 years
|
Through study completion, approximately 4 years
|
|
|
(Part 1A and 1B) Composite complete remission (CRc)
Periodo de tiempo: Through study completion, approximately 4 years
|
In participants with AML or MDS/AML only
|
Through study completion, approximately 4 years
|
|
(Part 1A and 1B) Red blood cell (RBC) and platelet transfusion independence for at least 8 weeks
Periodo de tiempo: Through end of treatment, up to approximately 4 years
|
In participants with AML or MDS/AML only
|
Through end of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Duration of response (DOR)
Periodo de tiempo: Through study completion, approximately 4 years
|
Through study completion, approximately 4 years
|
|
|
(Part 1A and 1B) Time to response (TTR)
Periodo de tiempo: Through study completion, approximately 4 years
|
In participants with AML or MDS/AML only
|
Through study completion, approximately 4 years
|
|
(Part 1A and 1B) Event free survival (EFS)
Periodo de tiempo: Through study completion, approximately 4 years
|
In participants with AML or MDS/AML only
|
Through study completion, approximately 4 years
|
|
(Part 1A and 1B) Overall survival (OS)
Periodo de tiempo: Through study completion, approximately 4 years
|
Through study completion, approximately 4 years
|
|
|
(Part 1A and 1B) Marrow response
Periodo de tiempo: Through end of treatment, up to approximately 4 years
|
In participants with CMML only
|
Through end of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Number of participants with erythroid-, neutrophil-, platelet or spleen-response
Periodo de tiempo: Through end of treatment, up to approximately 4 years
|
In participants with CMML only
|
Through end of treatment, up to approximately 4 years
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Neoplasias
- Enfermedad crónica
- Atributos de la enfermedad
- Enfermedades Genéticas Congénitas
- Neoplasias por tipo histológico
- Enfermedades hematológicas
- Leucemia Mieloide
- Enfermedades mielodisplásicas-mieloproliferativas
- Enfermedades de la médula ósea
- Leucemia
- Síndromes mielodisplásicos
- Enfermedades y anomalías congénitas, hereditarias y neonatales
- Condiciones Patológicas, Signos y Síntomas
- Enfermedades hemic y linfáticas
- Deficiencia de GATA2
- Leucemia Mieloide Aguda
- Leucemia Mielomonocítica Crónica
- posaconazol
Otros números de identificación del estudio
Otros números de identificación del estudio
- S241656-292
- 2025-525128-88-00 (Ctis)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data.
Access can be requested for all interventional clinical studies:
- used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
- where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope.
In addition, access can be requested for all interventional clinical studies in patients:
- sponsored by Servier
- with a first patient enrolled as of 1 January 2004 onwards
- for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.
Marco de tiempo para compartir IPD
Criterios de acceso compartido de IPD
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- CIF
- RSC
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .